Shares of Cleveland BioLabs Inc. (NASDAQ: CBLI), a biotechnology company engaged in the development of biodefense, tissue protection and cancer treatment drugs that are based on the concept of modulation of cell death for therapeutic benefit, are soaring today after the company reported strong survival results that met the primary endpoint of its Good Laboratory [...]
Recent Comments